Detalhe da pesquisa
1.
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
Cell
; 137(5): 835-48, 2009 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-19490893
2.
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
Cancer Cell
; 12(1): 81-93, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17613438
3.
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Nature
; 462(7276): 1070-4, 2009 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20033049
4.
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Cancer Cell
; 9(6): 485-95, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16730237
5.
LKB1 modulates lung cancer differentiation and metastasis.
Nature
; 448(7155): 807-10, 2007 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-17676035
6.
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Proc Natl Acad Sci U S A
; 106(46): 19503-8, 2009 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-19850869
7.
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
Proc Natl Acad Sci U S A
; 106(2): 474-9, 2009 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-19122144
8.
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.
J Clin Invest
; 117(2): 346-52, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17256054
9.
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
Clin Cancer Res
; 14(20): 6478-86, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18927287
10.
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Cancer Res
; 67(10): 4933-9, 2007 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17510423
11.
PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Clin Cancer Res
; 21(6): 1487-96, 2015 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25564152
12.
[Reconstruction and expression of green fluorescent protein and aquaporin 7 fusion recombinant vector].
Zhonghua Nan Ke Xue
; 10(11): 819-23, 2004 Nov.
Artigo
em Chinês
| MEDLINE | ID: mdl-15595681
13.
ß-catenin contributes to lung tumor development induced by EGFR mutations.
Cancer Res
; 74(20): 5891-902, 2014 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25164010
14.
Contrast agents for quantitative microCT of lung tumors in mice.
Comp Med
; 63(6): 482-90, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24326223
15.
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Clin Cancer Res
; 18(18): 4973-85, 2012 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22806877
16.
A dual role for the immune response in a mouse model of inflammation-associated lung cancer.
J Clin Invest
; 121(6): 2436-46, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21537082
17.
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Nat Med
; 17(7): 875-82, 2011 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21706030
18.
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.
Cancer Cell
; 20(3): 400-13, 2011 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-21907929
19.
Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.
Cell Stem Cell
; 7(1): 127-33, 2010 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20621056
20.
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Cancer Res
; 70(6): 2485-94, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20215504